Safety, immunogenicity, and clinical efficacy of durvalumab in combination with folate receptor alpha vaccine TPIV200 in patients with advanced ovarian cancer: a phase II trial

Dmitriy Zamarin, Sven Walderich, Aliya Holland, Qin Zhou, Alexia E. Iasonos, Jean M. Torrisi, Taha Merghoub, Lewis F. Chesebrough, Autumn S. Mcdonnell, Jacqueline M. Gallagher, Yanyun Li, Travis J. Hollmann, Rachel N. Grisham, Courtney L. Erskine, Mathew S. Block, Keith L. Knutson, Roisin E. O'Cearbhaill, Carol Aghajanian, Jason A. Konner

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Fingerprint

Dive into the research topics of 'Safety, immunogenicity, and clinical efficacy of durvalumab in combination with folate receptor alpha vaccine TPIV200 in patients with advanced ovarian cancer: a phase II trial'. Together they form a unique fingerprint.

Medicine & Life Sciences